Notice of Intent to Sole Source; Monument Medical
ID: 25-000116Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Surgical and Medical Instrument Manufacturing (339112)

PSC

MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES (6515)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Original Source

https://sam.gov/opp/65b3f50ad556415db187d3eea9070be6/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to QuVA Pharma, Inc. for the procurement of compounded intravenous (IV) narcotics for patient care at the NIH Clinical Center. This acquisition aims to secure sterile compounded products that meet the quality standards necessary for ongoing patient treatment, as QuVA Pharma is the sole distributor of these specific IV narcotics in the U.S. market. Interested parties are invited to express their interest and capabilities regarding this procurement, with comments due by November 15, 2024, at 10 AM EST, directed to Kristin Nagashima at kristin.nagashima@nih.gov.

    Point(s) of Contact
    Kristin Nagashima
    kristin.nagashima@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent to Sole Source; Monument Medical
    Currently viewing
    Special Notice
    Similar Opportunities
    Notice of Intent to Sole Source – TheraDoc subscription
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) Clinical Center intends to award a firm fixed-price purchase order for subscription services related to the TheraDoc application, exclusively owned by Premier Healthcare LLC. This procurement aims to secure applications, support, maintenance, and training for the TheraDoc clinical surveillance solution, which is critical for enhancing healthcare delivery and patient safety. The acquisition will follow the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, allowing for a sole-source solicitation due to the unique nature of the services required. Interested parties may express their capabilities and submit comments to the NIH by November 21, 2024, with inquiries directed to Ryssa Nix at Ryssa.nix@nih.gov.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Notice of Intent to Sole Source – Articulate Global
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Articulate Global, LLC for the renewal of licenses for the Articulate 360 suite of e-learning authoring tools. This procurement aims to provide the NIH Clinical Center Nursing Department with continued access to a suite of customizable tools essential for developing and maintaining over 60 online courses that have been created since 2015. The renewal is critical as it allows the Nursing Department to efficiently update existing courses without the need to transition to a new vendor, which would significantly disrupt their operations. Interested parties may express their interest and capabilities by contacting Kristin Nagashima, Contract Specialist, via email at Kristin.nagashima@nih.gov by January 17, 2025, at 5 PM EST.
    Biological Therapeutics Product Development Subject Matter Expert Consultants
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for consulting services from subject matter expert (SME) consultants to support the development of biological therapeutics. The primary objective is to engage experts who can provide technical recommendations across various phases of drug discovery and development, including chemistry, regulatory affairs, and clinical trial design, particularly for novel therapeutics aimed at neurological disorders and rare genetic conditions. This initiative is crucial for advancing NIH's drug discovery programs, ensuring that innovative biologics progress efficiently through clinical evaluation. Interested vendors should note that the contract has a performance period of one year, with two optional extensions, and proposals must be submitted by January 27, 2025. For further inquiries, potential bidders can contact Shayna Simpson at shayna.simpson@nih.gov or Kelly Dempsey at kelly.dempsey@nih.gov.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    6505--Cyclobenzaprine Tablets (VA-25-00015093)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Cyclobenzaprine HCL Tablets under solicitation number 36E79725R0009. This unrestricted procurement aims to secure a reliable supply of these essential pharmaceuticals for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC), reflecting the government's commitment to providing necessary medications to veterans and associated healthcare systems. The contract will have an initial duration of one year, with the possibility of four additional one-year extensions, and interested vendors must provide specific drug labeling along with a unique National Drug Code (NDC). The RFP is expected to be released electronically around December 20, 2024, with a submission deadline set for January 3, 2025. For further inquiries, interested parties can contact Kenneth Lay at Kenneth.Lay@va.gov or by phone at 708-786-4879.
    65--Illumina Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Heart, Lung, and Blood Institute (NHLBI), intends to award a non-competitive contract to Illumina, Inc. for the supply of "Illumina Reagents and Consumables" essential for various sequencing and genotyping systems. This procurement is driven by the unique operational needs of NIH-owned systems, as confirmed by market research indicating that only Illumina can provide the proprietary reagents necessary to maintain research integrity and support ongoing studies. The contract performance period is set from September 3, 2025, to September 2, 2030, and interested parties may submit capability statements for review by January 6, 2025; however, this is not a solicitation for proposals. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or by phone at +1 301 496 2153.
    Naloxone
    Active
    Court Services And Offender Supervision Agency
    The Court Services and Offender Supervision Agency (CSOSA) is soliciting proposals for the procurement of 450 packages of Naloxone 2 Dose Nasal Spray. This solicitation aims to acquire essential pharmaceutical products that play a critical role in emergency medical responses to opioid overdoses. The contract will be awarded under a firm-fixed price purchase order, with a submission deadline for quotations set for January 7, 2025. Interested vendors can direct inquiries to Matthew Collins at matthew.collins@csosa.gov or by phone at 202-369-7635 for further details on compliance and submission requirements.
    Preventative Maintenance and Service Package for the Mediso nanoScan PET/CT animal imager
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking qualified vendors to provide a Preventative Maintenance and Service Package for the Mediso NanoScan PET/CT animal imager. This procurement involves a comprehensive service plan that includes a 12-month base period followed by four optional 12-month periods, commencing on February 10, 2025, at the Biomedical Research Center in Baltimore, Maryland. The Mediso NanoScan PET/CT is crucial for advanced imaging in biomedical research, and the selected vendor must demonstrate technical capabilities, customer support, and delivery speed as part of the evaluation process. Interested parties should note that the Request for Quotation (RFQ) number is 75N95025Q00104, with responses due by January 6, 2025. For further inquiries, vendors can contact Andrew Varley at andrew.varley@nih.gov or Joshua T. Lazarus at Josh.Lazarus@nih.gov.
    iThenticate Plagiarism Detection Software License (or equal)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for a software license for iThenticate, a plagiarism detection tool essential for the Intramural Research Program's manuscript preparations. The software must provide capabilities to check for plagiarism, assess manuscript originality, and identify AI-generated content, aligning with modern academic integrity standards. This acquisition is crucial for maintaining research integrity and improving the quality of scholarly outputs within government-funded research initiatives. Interested vendors must submit their quotations by 5:00 p.m. Eastern Time on January 10, 2025, referencing Solicitation Number 75N95025Q00070-RFQ, and can direct inquiries to Iris Merscher at iris.merscher@nih.gov or by phone at 301-827-2547.